<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03715140</url>
  </required_header>
  <id_info>
    <org_study_id>IR.MUMS.MEDICAL.REC.1397.118</org_study_id>
    <nct_id>NCT03715140</nct_id>
  </id_info>
  <brief_title>Crucumin Effects on the Immune System in Osteoarthritis Patients</brief_title>
  <official_title>Evaluation of the Crucumin Effects on the Cellular and Humoral Immune Systems in Osteoarthritis Patients; a Randomised Double Blind Placebo Control Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mashhad University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mashhad University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the effects of crucumin on cellular and humoral immune system in patients with
      osteoarthritis will be investigated. Concentration of CXCL8, April, CX3CL1 and IL-17 will be
      evaluated with ELISA. TH-1, TH-17, TReg and Ly.B cells count will be measured by
      Flowcytometry. MicroRNA-720, MicroRNA-155, MicroRNA-16 and MicroRNA-146a gene expression will
      be measured with Real Time PCR technique.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to evaluate the effect of the active ingredient of crucumin on
      the reduction of symptoms of osteoarthritis. Of the 30 patients participating in this study,
      a blood sample will be taken at the beginning of the study, and then after three months of
      taking the crucumin. To evaluate the response to treatment, after each person sampling, we
      will analyze cell count for Th-1, Th-17, TReg and Ly.B by flowcytomtry method. Also we will
      measure cytokines level of IL-17, CXCL8, CX3CL1 and April by ELISA method. Finally we
      evaluate the gene expression of MicroRNA-720, MicroRNA-155, MicroRNA-146a and MicroRNA-16 by
      Real Time PCR technique.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IL-17</measure>
    <time_frame>Baseline</time_frame>
    <description>Cytokine level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-17</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Cytokine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TH-1</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Cell counting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MicroRNA-720</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Gene expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CXCL8</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Cytokine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CXCL1</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Cytokine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>April</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Cytokine level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TH-17</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Cell counting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TReg</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Cell counting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ly.B</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Cell counting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MicroRNA-155</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Gene expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MicroRNA-146a</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Gene expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MicroRNA-16</measure>
    <time_frame>Baseline and three months</time_frame>
    <description>Gene expression</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Patients who will recieve crucumin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who prescribing crucumin 80 mg daily for three months will be evaluated. A sample will be taken before taking the drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients who will receive placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients who prescribing placebo daily for three months will be evaluated. A sample will be taken before taking the placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crucumin</intervention_name>
    <description>Evaluation of the effect of Crucumin in patients with osteoarthritis</description>
    <arm_group_label>Patients who will recieve crucumin</arm_group_label>
    <other_name>nanocrucumin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Patients who will receive placebo</arm_group_label>
    <other_name>Crucumin placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Osteoarthritis patients who have been diagnosed with a rheumatologist physician based on
        clinical examinations and laboratory tests

        Exclusion Criteria:

        Affected by any other acute or chronic underlying disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mojgan Mohammadi, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mojgan Mohammadi, Ph.D</last_name>
    <phone>0098 51 38012762</phone>
    <email>mozhganmohammadi69@yahoo.co.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mahdi Atabaki, Student</last_name>
    <phone>0098 51 38012762</phone>
    <email>atabaki80@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mahdi Atabaki</name>
      <address>
        <city>Mashhad</city>
        <zip>9188815435</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahdi Atabaki, Ph.D Candidate</last_name>
      <phone>+989303043900</phone>
      <email>atabaki80@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mashhad University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Dr. Mojgan Mohammadi</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Osteoarthritis, Crucumin, Flowcytometry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Preferring the data to remain confidential</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

